Articles tagged with T Cell Lymphoma
CAR T-cell therapies have demonstrated durable remission and survival rates of over 59% for patients with refractory NHL. Researchers found that sustained responses were consistent across long-term follow-up analyses, suggesting potential for these therapies as the standard of care for hematologic malignancies.
A Phase 2 study of axi-cel, a CD19-targeting CAR T cell therapy, reported remarkable improvement in outcomes for patients with relapsed or refractory large B-cell lymphoma. The study showed that 42% of patients remained in remission at 15 months, with complete responses in 54% and measurable responses in 82%.
A team from Technical University of Munich has discovered a 'shut-off switch' in immune cells called PD-1 that prevents T cell Non-Hodgkin's lymphoma. The study found that PD-1 can turn off defective T cells at an early stage, preventing them from becoming tumor cells.
Researchers have discovered a method to target cancerous T-cells while sparing healthy ones, which are essential to the immune system. This breakthrough could lead to new therapeutic approaches for rare and aggressive T-cell lymphoma, which has been difficult to treat without damaging healthy T-cells.
CAR T-cell therapy, approved by the FDA, has been shown to double long-term survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma. The treatment, offered at UChicago Medicine, involves reprogramming a patient's immune system to detect and destroy cancer cells.
Scientists at UC San Diego uncover a previously unknown link between non-coding DNA regions and the formation of immune cells. The discovery reveals a precise mechanism for the pairing of promoter and enhancer elements, which brings them into close proximity to initiate immune cell development.
Researchers report a remarkable treatment response in a patient with recurrent diffuse large-B-cell lymphoma (DLBCL), where CAR T-cell therapy induced complete remission of a brain metastasis. The treatment also showed spontaneous re-expansion of CAR T-cells after a subcutaneous tumor recurrence, leading to further research into the me...
Researchers at the GW Cancer Center discovered that removing the HDAC11 enzyme from T-cells enhances their ability to attack cancer tumors. The study highlights this enzyme as a key regulator of T-cell function and a potential target for immunotherapy.
The study found that KTE-C19 induced a significant response rate in patients with diffuse large B-cell lymphoma, with 76% overall response and 47% complete remission. Serious adverse events were reported, but the team developed guidelines to manage side effects across multiple institutions.
In a phase 1 clinical study of 32 participants with advanced B cell non-Hodgkin lymphoma, immunotherapy with defined subsets of T cells showed strong antitumor activity. The therapy was found to be more effective when combined with specific ratios of CD4 and CD8 CAR-T cells and pretreatment chemotherapy regimen.
Researchers at Fred Hutchinson Cancer Center report promising results from an early-phase study of CAR T cell treatment, achieving complete remission in 50% of patients. The study's findings suggest that a defined composition of CAR T cells can increase efficacy while minimizing toxic side effects.
PharmaMar announces the start of a multicenter study evaluating plitidepsin's efficacy in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma. The primary endpoint is overall response rate, while secondary endpoints include duration of response, progression-free survival, and pharmacokinetic characteristics.
Dr. Riddell will discuss recent advances in CAR T-cell therapy, which has shown sustained regression in previously relapsing cases of B-cell malignancies. His presentation aims to outline steps to improve targeting and reduce side effects.
Researchers found that younger T cells are critically important in T cell immunotherapy and can be more effective when collected earlier. This discovery has the potential to change clinical management in T cell immunotherapy.
A review article highlights barriers to overcome in CAR T cell therapy for lymphoma, including physical barriers and immunosuppression. The study explores factors related to tumor biology and immunology compared to treatment response in patients with lymphoma.
Researchers have found a molecular 'switch' that safely controls severe side effects associated with haploidentical stem cell transplantation. The switch, inducible caspase 9 (iC9), is activated by a single dose of bio-inert chemical and clears symptoms without jeopardizing graft function.
The Phase 1-2a clinical trial demonstrated a 92% objective response rate, including complete remissions in eight patients and partial remissions in four patients. Four out of seven evaluable patients with chemotherapy-refractory DLBCL achieved complete remissions, with durations ranging from 9 to 22 months.
Researchers at Fred Hutchinson Cancer Center successfully infused large numbers of donor T-cells specific for the Wilm's Tumor Antigen 1 (WT1) to prolong survival in high-risk leukemia patients. The treatment showed improved anti-leukemic activity and reduced graft-vs.-host-disease.
A team of scientists from the University of Southampton will explore ways to prevent graft-vs-host disease (GVHD) and improve bone marrow transplants by stimulating donor T-cells to target cancerous cells while reducing immune system reactions.
Researchers have discovered that a leukemia drug called Campath can effectively treat L-CTCL without increasing the risk of infections. The treatment targets only circulating cancerous T-cells, while sparing tissue-resident T-cells that provide frontline immune protection.
A Phase III clinical trial found that adding gemtuzumab ozogamicin to standard chemotherapy improved event-free and overall survival in newly-diagnosed acute myeloid leukemia patients aged 50-70. The treatment also reduced toxicity while providing therapeutic benefits.
Researchers have identified a crucial role for TCF-1 in regulating T-cell development, which could lead to improved treatments for immune-suppressed patients. Notch triggers the process of T-cell development and turns on expression of TCF-1, but not itself.
GSK-3 inhibitors may have adverse effects on the heart, while NMDA molecules could provide nerve cell protection, highlighting the need for careful risk-benefit assessments. These findings have implications for developing new treatments for conditions such as Alzheimer's disease and diabetes.
A team of researchers has identified IL-15 as a key player in the development of enteropathy-associated T cell lymphoma, a high-grade invasive lymphoma associated with severe celiac disease. Treatment with an antibody directed at IL-15 successfully wiped out intraepithelial lymphocytes in mice overexpressing human IL-15.
A rare case of adult T-cell leukemia/lymphoma (ATLL) with multiple lymphomatous polyposis is reported, highlighting the importance of endoscopic evaluation to differentiate neoplastic intestinal lesions from infectious enterocolitis. The patient presented with fever, watery diarrhea, and colonic involvement without leukemic change or v...
The disease varies by race, sex, and geographic area, with higher incidence among blacks and men. The nationwide rates of the disease were last documented in 1992.
Researchers found a substantial rise in cutaneous T-cell lymphoma cases over three decades, with highest rates in San Francisco and lowest in Iowa. The disease disproportionately affects men, Blacks, and those living in affluent areas.
The LAT protein is essential for T-cell activation and a normal immune response. Mutations in the protein can lead to unbalanced signaling pathways, potentially causing autoimmune disorders.